Friday, 16 October 2026European Markets

NEPI ROCKCASTLE Stock Went Up By Over 11% So Far On Tuesday

Loading stream...

Shares of NEPI Rockcastle, one of the leading owners and operators of shopping centers across Central and Eastern Europe, experienced an astounding 11.11% spike to EUR6.00 Tuesday after three consecutive sessions of losses. Furthermore, its listing on AEX-Index rose 0.96% to EUR779.93.

NEPI Rockcastle's Strategy and Influence

NEPI Rockcastle currently manages 52 retail properties that received 244 million visits in 2021, drawing on their financial strategy of maintaining adequate liquidity, conservative gearing and diversifying debt structures to attract visitors. They have received investment grade ratings from Standard & Poor's (BBB, stable outlook) and Fitch (BBB, positive outlook).

Financial Indicators

NEPI Rockcastle earned an earnings per share (EPS) of EUR0.71, while their price-to-earnings (PE) ratio stands at 8.45, meaning investors are currently paying EUR8.45 per euro of annual earnings.

Volatility Factors

As far as volatility goes, NEPI Rockcastle has experienced fluctuation across weekly, monthly and quarterly averages. Last week saw an average negative 2.30% change; last month experienced positive shift of 0.333% while quarter showed notable increases of 4.92 %.

NEPI Rockcastle's remarkable surge in share price against previous sessions' losses is certainly noteworthy; however, investors should remain wary given its recent volatility. Given NEPI Rockcastle's resilient approach and standing in the market place may make this an exciting prospect.

More news about NEPI ROCKCASTLE (NRP.AS).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com